Ann Arbor, MI – According to filings with the U.S. Securities and Exchange Commission, Genomenon is raising $19,999,994.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Michael Klein played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Genomenon
Genomenon is a genomic health IT company that keeps pace with the constant advancements made in genomics and connects that research to patient DNA to help diagnose and treat patients with rare genetic diseases and cancer. The Mastermind Genomic Search Engine is used by hundreds of genetic labs worldwide to accelerate diagnosis, increase diagnostic yield, and assure repeatability in reporting genetic testing results. Mastermind Genomic Landscapes inform pharmaceutical and bio-pharma companies on precision medicine development, deliver genomic biomarkers for clinical trial target selection, and support CDx regulatory submissions with empirical evidence. Genomenon was named 2020 Global Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan.

To learn more about Genomenon, visit http://www.genomenon.com/

Contact:
Michael Klein, Chief Executive Officer
734-794-3075
klein@genomenon.com
https://www.linkedin.com/in/mikeklein/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved